Oncodermatology: Optimizing Skincare for Patients With Cancer CE

Frontline Sorafenib Shows Promising Outcomes in Metastatic Uveal Melanoma

Investigational NDA Submitted to FDA for CD-19+ Lymphoma/Leukemia

Videos Trending
 

Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: A randomised, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable gastric / gastroesophageal junction adenocarcinoma\
This Around the Practice program brings together a multidisciplinary panel to examine evolving perioperative strategies for resectable gastroesophageal and gastric cancers, with a particular focus on integrating systemic therapy, immunotherapy, and surgical planning. Panelists review emerging data from key studies, including the DFLOT regimen evaluated in the MATTERHORN trial, and discuss how these findings may influence real world care once regulatory decisions are finalized. Throughout the program, the experts highlight the importance of accurate staging, appropriate patient selection, and careful assessment of treatment tolerance when approaching complex early stage disease. The discussion incorporates practical considerations faced in both academic and community settings, including nutrition support, feeding access, performance status preservation, germline testing, and the coordination required for patients living at a distance from major centers.

Featured Video

Optimizing Hypomethylating Therapy in Myelodysplastic Syndromes
This program focuses on optimizing the use of oral hypomethylating agents (HMAs) in myeloid malignancies, primarily high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). A multidisciplinary panel of hematologists, transplant specialists, and an oncology nurse practitioner discusses real-world cases involving TP53-mutated MDS and proliferative CMML, both complicated by cytopenias, comorbidities, logistical challenges, and patient preferences. Panelists review evidence supporting oral decitabine/cedazuridine as a practical and clinically effective therapy comparable to intravenous HMAs. They also discuss transplant candidacy, timing, and the emerging role of combination therapies such as venetoclax with oral HMAs. Across the program, speakers emphasize individualized patient-centered care, balancing disease control with quality of life, treatment burden, telemedicine integration, and realistic expectations. The experts conclude that oral HMA therapy will lead to broader community-based treatment, greater patient autonomy, and future expansion of combination regimens and clinical trials.

Featured Video Long-Term Data on Oral Hypomethylating Agents
Explore the latest advancements in oral hypomethylating agents for MDS and CMML, emphasizing their efficacy, patient convenience, and treatment strategies.

FDA Approves Narsoplimab for HSCT-Associated Thrombotic Microangiopathy

Minority/Medicaid Status Associated With Lower PRO Utilization in Oncology

Videos ‘Seamlessly’ Integrating Bioimpedance Spectroscopy Into Clinical Workflows Trending What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting



       

Hematology/Oncology Update            January 2026
Original Research Multimedia Perspective and Commentary

SEQUOIA Arm C (Zanubrutinib for Del[17p] Treatment-Naive [TN]-CLL/SLL) and Arm D (Zanubrutinib + Venetoclax for TN-CLL/SLL)
Experts discuss the critical advancements in biomarker-driven frontline treatment for high-risk chronic lymphocytic leukemia (CLL), emphasizing the SEQUOIA trial’s evidence supporting targeted Bruton tyrosine kinase inhibitor monotherapy and combination therapies with venetoclax as effective, personalized, and well-tolerated options that improve progression-free survival and patient quality of life.

Featured Video Adverse Effect Management and Monitoring Patients on BTK Inhibitors
Experts discuss how second-generation Bruton tyrosine kinase (BTK) inhibitors have enhanced chronic lymphocytic leukemia (CLL) management by offering improved tolerability and flexible dosing strategies that allow personalized, long-term therapy with manageable adverse effects and effective toxicity mitigation, thereby maintaining disease control while preserving patients’ quality of life.



 

Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer

Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML

Videos Bioimpedance Spectroscopy is Allowing for Lymphedema Reduction in Breast Cancer
Trending Oncology On the Go Wrapped: The Top 10 Podcast Episodes of 2025